Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-04

FDA Approved: AMBRISENTAN — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

The FDA approved a supplemental application for Ambrisentan submitted by Aurobindo Pharma Limited under ANDA216531. This pertains to the generic product and con…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)